Astymin-SN

Supply of aminoacids as part of a parenteral nutrition regimen in severe forms of hepatic insufficiency with or without hepatic encephalopathy when oral or enteral nutrition is impossible or insufficient or contraindicated.

Adults: Astymin-SN is usually IV drip-infused at a single dose of 500 mL. The standard infusion rate is ≥180 min/500 mL.

The dosage may be adjusted according to the patient's age, symptoms and body weight.

Administration: If administered via central venous line, 500 mL should be mixed with a carbohydrate-containing solution and be infused continuously via central vein for 24 hrs.

Patients with serious renal disorder (the symptoms may be aggravated due to overload of nitrogen compounds) and with amino acid metabolism abnormality other than liver disorder (imbalance of amino acids may be aggravated).

Isoleucine have anticatabolic and antitardive dyskinesia activity. It also used as a dietary supplement for patients with mapple syrup urine disorder.

There is no report to indicate the interaction with other drug.

Among 243 cases studied prior to the time of approval, 9 adverse reactions (3.7%) were reported in 9 cases (3.7%). The commonly reported adverse reactions by the time of approval included nausea or queasy (0.8% each), sweaty, increased transient blood ammonia level, vascular pain, urticaria, tremor limb by hypoglycaemia (0.4% each).

Each infusion bag of Astymin-SN contains the following: See Table 1.

It also contains the following inactive ingredients: See Table 2.

The pH and the osmotic pressure ratio are shown in Table 3.